Navigation Links
Moffitt Cancer Center researchers test drug combinations to prevent graft vs. host disease
Date:6/26/2012

Researchers at Moffitt Cancer Center have conducted a clinical trial aimed at preventing graft vs. host disease (GVHD) in patients who have received hematopoietic (blood) cell transplants (HCT). The study, comparing the drug tacrolimus (TAC) in combination with either methotrexate (MTX ) or sirolimus (SIR), found that the sirolimus/tacrolimus (SIR/TAC) combination was more effective in preventing grades II-IV acute GVHD and moderate-severe chronic GVHD after allogeneic blood cell transplantation.

The study randomized 74 patients, ages 16 to 70, to receive either SIR/TAC or MTX/TAC. Patients were stratified by donor relation (siblings or matched, unrelated individuals) and age.

Their study was published in a recent issue of Haematologica, the journal of the European Hematology Association.

"Graft vs. host disease poses major health problems for patients who have received hematopoietic cell transplants and threatens the long-term success of their transplant," said Joseph Pidala, M.D., M.S., a medical oncologist and study principal investigator. "Existing pharmacologic strategies do not adequately prevent acute graft vs. host disease following allogeneic hematopoietic (blood) cell transplantation, and effective acute GVHD prevention is an important clinical goal necessary to ensure the long-term success of transplantation."

According to the authors, their study design mandated at least one year of sirolimus therapy in order to both limit the risk from chronic GVHD development and to promote the patients' immune tolerance based on the "reconstitution" of the patients' immune cells, called regulatory T cells, or "Tregs."

"Our hypothesis was that SIR-based immune suppression would suppress alloreactive T cells, support the recovery of the immune system's Tregs, and more effectively prevent GVHD," explained Pidala.

Results showed that on days 30 and 90 post transplantation, SIR/TAC-treated patients had "a significantly greater proportion of regulatory T cells among the CD 4 immune cells in their peripheral blood" and their regulatory Tregs were "functional."

The authors suggested that the "net benefit" observed in Treg reconstitution with SIR/TAC-treated patients was likely due to both the suppression of immune systems' non-Treg CD4 T cells by sirolimus, as well as the lower tacrolimus exposure for these patients as compared to patients on the MTX/TAC arm of the study.


'/>"/>

Contact: Patty Kim
patty.kim@moffitt.org
813-745-7322
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Sun exposure and cutaneous HPV infection found synergistic in skin cancers, Moffitt says
2. Myelodysplastic syndrome treated with deferasirox shows beneficial iron reduction, Moffitt says
3. Moffitt researchers: Darwins principles say cancer will always evolve to resist treatment
4. Moffitt researcher, colleagues find success with new immune approach to fighting some cancers
5. Moffitt Cancer Center researchers develop and test new anti-cancer vaccine
6. Moffitt Cancer Center researchers identify drivers of sarcoma growth and survival
7. Researchers creating designer lymph nodes based on Moffitts Total Cancer Care initiative
8. Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks
9. Moffitt researcher publishes book on nutritional management of cancer treatment effects
10. Moffitt researchers find adolescents with cancer concerned about their future reproductive health
11. Moffitt Cancer Center researchers working at frontiers of melanoma research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... In light of recent heavy flooding in Houston, ... contaminated well water throughout the Houston area. , Heavy floodwaters have led to destroyed ... to contaminants. Residents may not even be aware of the contamination of their water ...
(Date:5/24/2016)... Los Angeles, California (PRWEB) , ... May 24, 2016 , ... ... donated $4,000, food, clothing, supplies and other necessities to Eunime Orphanage in Tijuana, Mexico ... eat pizza and play games at Peter Piper Pizza. , More than 15 ...
(Date:5/24/2016)... ... May 24, 2016 , ... Global Lyme Alliance (GLA), a ... that it has named Scott Santarella as its new CEO. , Santarella ... (ALCF) in San Francisco, where he successfully helped to grow the organization from ...
(Date:5/24/2016)... ... May 24, 2016 , ... PhysicianOne Urgent Care, advocators in ... tick bites and how to avoid being bitten this spring. , The official ... , Ticks, small spider-like insects, are known for attaching themselves to their prey while ...
(Date:5/24/2016)... ... May 24, 2016 , ... Applications such as ... are widely used for cell and protein analysis. Keeping updated on practical considerations ... efficiency in these areas. , LabRoots introduces a new complementary interactive virtual ...
Breaking Medicine News(10 mins):
(Date:5/20/2016)... , May 20, 2016 ... Review, H1 2016" market research report with comprehensive ... (Psoriasis Vulgaris), complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ... and press releases. It also reviews key players ...
(Date:5/19/2016)... Cellvizio Highlighted in Physician Presentations and ... 91 st Congress of the Japan Gastroenterological ... MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary ... Cellvizio platform is being highlighted at two major ... of May. The first meeting highlighting Cellvizio is ...
(Date:5/19/2016)... 2016 According to a new market research ... (U.S., Germany , France , ... and Japan )", published by MarketsandMarkets, The market ... CAGR of 13.9% from 2016 to 2021.      (Logo: ... data Tables spread through 26 Pages and in-depth TOC on ...
Breaking Medicine Technology: